The management of a Pharmacovigilance cycle, from Phase I-IV to post marketing surveillance, represents a crucial aspect for pharmaceutical and biotechnology companies whose priority is to safeguard the impact of drugs on human beings. At the same time, this would be a significant challenge in terms of time, budget and staff resources.
CROS NT is dedicated to providing customers with a complete and flexible portfolio of drug safety and risk management services. As providers of Pharmacovigilance services, CROS NT is dedicated to collecting, monitoring, researching, assessing and evaluating drug safety information to detect new adverse reactions and communicating the research to health authorities. This allows us to help companies decrease costs, improve performance and achieve deadlines.
CROS NT relies on its proven expertise in commercial safety database management (Oracle AERS and ARGUS) and individual customer database implementation to enhance the accuracy of safety reports across the Serious Adverse Event life-cycle.
AERS SOLUTION
CROS NT is focused on identifying all adverse consequences of medication exposure and understands that accurate reporting is essential to empower pre and post marketed drug safety programs. Therefore, CROS NT uses AERS support, a validated Oracle safety system for the management and tracking of Serious Adverse Effects.
In April 2010, Barbara became the head of CROS NT’s Pharmacovigilence unit. In her prior experience with CROS NT, she was a Drug Safety Officer as well as a Senior Data Manager. Barbara graduated from the University of Bologna in Italy with a degree in “Informazione Scientifica sul Farmaco”.
